Concepedia
Statistics
Publications
9
Citations
1.1K
H-Index
Active since
1989
Affiliations
Active Biotech (Sweden)(Current)
Lund University
Johns Hopkins University
Sidney Kimmel Comprehensive Cancer Center
Anders Björk is an author at Active Biotech (Sweden) specializing in medicine, pharmacology, and psychopharmacology.
Top concepts
MedicinePharmacologyPhysiologyNeuropharmacologyPsychopharmacologyCocaineAddictionEducationImmunologyPsychiatry
Publications per year
1989–2011
Identification of Human S100A9 as a Novel Target for Treatment of Autoimmune Disease via Binding to Quinoline-3-Carboxamides
Per Björk, Anders Björk, Thomas Vogl et al. · PLoS Biology · 2009 · 352 citations · Full text
Clinical Immunology, Drug Target, Immunology +20
Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
Michael Häggman, Walter M. Stadler, Jeffrey R. Gingrich et al. · Journal of Clinical Oncology · 2011 · 208 citations
Synthesis and Biological Evaluation of New 1,2-Dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for Treatment of Autoimmune Disorders: Structure−Activity Relationship
Stig Jönsson, Gunnar Andersson, Tomas Fex et al. · Journal of Medicinal Chemistry · 2004 · 156 citations
Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors
Anders Olsson, Anders Björk, Johan Vallon‐Christersson et al. · Molecular Cancer · 2010 · 90 citations · Full text
Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer
John T. Isaacs, David Z. Qian, Susan L. Dalrymple et al. · The Prostate · 2006 · 87 citations
1–5 of 9